Inhalable curcumin formulations: Micronization and bioassay

Chemical Engineering Journal

Volumn 279, Issue , 2015, Pages 799-808

  Kurniawansyah, Firman ^a,b   Duong, Hien T T ^a   Luu, Thai Danh ^a,c   Mammucari, Raffaella ^a   Vittorio, Orazio ^a   Boyer, Cyrille ^a   Foster, Neil ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b DEPARTMENT OF ELECTRICAL ENGINEERING   (Indonesia)

^c CAN THO UNIVERSITY   (Viet Nam)

Author keywords

ARISE; Flow cytometry; Inhalation delivery; Lung cancer; Micronization; Supercritical fluids

Indexed keywords

AERODYNAMICS; BIOASSAY; BIOLOGICAL ORGANS; CARBON; CARBON DIOXIDE; CYTOLOGY; DISEASES; EFFLUENT TREATMENT; FLOW CYTOMETRY; SOLVENT EXTRACTION; SOLVENTS; SUPERCRITICAL FLUIDS;

AERO-DYNAMIC PERFORMANCE; ARISE; FLUORESCENCE LIFETIME IMAGING MICROSCOPY; HIGH-PRESSURE CARBON DIOXIDE; INHALATION DELIVERY; LUNG CANCER; MICRONIZATIONS; SOLVENT-EXTRACTION PROCESS;

CELLS;

EID: 84930958797     PISSN: 13858947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cej.2015.05.087     Document Type: Article

References (42)

1. Brain J.D. Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol. Ther. 2007, 9. pp. S-4-S-15.
2. Fiel S. History and evolution of aerosolized therapeutics: overview and introduction. Chest J. 2001, 120:87S-88S.
3. Chaturvedi N., Solanki H. Pulmonary drug delivery system: review. Int. J. Appl. Pharm. 2013, 5:7-10.
4. Chan H.-K. What is the role of particle morphology in pharmaceutical powder aerosols?. Exp. Opin. Drug Deliv. 2008, 5:909-914.
5. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:600-612.
6. Wong W., Crapper J., Chan H.-K., Traini D., Young P.M. Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. J. Pharm. Biomed. Anal. 2010, 51:853-857.
7. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392:1-19.
8. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 1996, 85:1142-1169.
9. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
10. Uekama K., Hirayama F., Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 1998, 98:2045-2076.
11. Srichana T., Suedee R., Reanmongkol W. Cyclodextrin as a potential drug carrier in salbutamol dry powder aerosols: the in-vitro deposition and toxicity studies of the complexes. Respir. Med. 2001, 95:513-519.
12. Evrard B., Bertholet P., Gueders M., Flament M.P., Piel G., Delattre L., Gayot A., Leterme P., Foidart J.M., Cataldo D. Cyclodextrins as a potential carrier in drug nebulization. J. Control. Release 2004, 96:403-410.
13. Chow A.L., Tong H.Y., Chattopadhyay P., Shekunov B. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24:411-437.
14. Hickey A.J., Martonen T.B., Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharm. Acta Helv. 1996, 71:185-190.
15. Mammucari R., Dehghani F., Foster N. Dense gas processing of micron-sized drug formulations incorporating hydroxypropylated and methylated beta-cyclodextrin. Pharm. Res. 2006, 23:429-437.
16. York P. Strategies for particle design using supercritical fluid technologies. Pharm. Sci. Technol. Today 1999, 2:430-440.
17. Fages J., Lochard H., Letourneau J.-J., Sauceau M., Rodier E. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol. 2004, 141:219-226.
18. Tandya A., Dehghani F., Foster N.R. Micronization of cyclosporine using dense gas techniques. J. Supercrit. Fluids 2006, 37:272-278.
19. Ober C.A., Kalombo L., Swai H., Gupta R.B. Preparation of rifampicin/lactose microparticle composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol. 2013, 236:132-138.
20. Lobo J.M., Schiavone H., Palakodaty S., York P., Clark A., Tzannis S.T. SCF-engineered powders for delivery of budesonide from passive DPI devices. J. Pharm. Sci. 2005, 94:2276-2288.
21. Kim Y., Sioutas C., Shing K. Influence of stabilizers on the physicochemical characteristics of inhaled insulin powders produced by supercritical antisolvent process. Pharm. Res. 2009, 26:61-71.
22. F. Kurniawansyah, R. Mammucari, N.R. Foster, Inhalable curcumin formulations by supercritical technology, Powder Technol. (2015) (forthcoming).
23. Mammucari R., Foster N. Dense gas technology and cyclodextrins: state of the art and potential. Curr. Org. Chem. 2008, 12:476-491.
24. Foster N.R., Sih R. Development of a novel precipitation technique for the production of highly respirable powders: the atomized rapid injection for solvent extraction process. Gas Expanded Liquids and Near-Critical Media: Green Chemistry and Engineering 2009, 309-347. ACS Books Department, Washington, DC. K. Hutcheson, A. Scurto, B. Subramaniam (Eds.).
25. de Melo S.A.B.V., Danh L.T., Mammucari R., Foster N.R. Dense CO2 antisolvent precipitation of levothyroxine sodium: a comparative study of GAS and ARISE techniques based on morphology and particle size distributions. J. Supercrit. Fluids 2014, 93:112-120.
26. Bhawana R., Bashniwal H., Buttar V., Jain N. Jain, characterization and antimicrobial study. J. Agric. Food Chem. 2011, 59:2056-2061.
27. Yallapu M.M., Jaggi M., Chauhan S.C. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov. Today 2012, 17:71-80.
28. Onoue S., Takahashi H., Kawabata Y., Seto Y., Hatanaka J., Timmermann B., Yamada S. Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J. Pharm. Sci. 2010, 99:1871-1881.
29. Suresh M.V., Wagner M.C., Rosania G.R., Stringer K.A., Min K.A., Risler L., Shen D.D., Georges G.E., Reddy A.T., Parkkinen J., Reddy R.C. Pulmonary administration of a water-soluble curcumin complex reduces severity of acute lung injury. Am. J. Respir. Cell Mol. Biol. 2012, 47:280-287.
30. Tomren M.A., Másson M., Loftsson T., Tønnesen H.H. Studies on curcumin and curcuminoids: XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin. Int. J. Pharm. 2007, 338:27-34.
31. Paradkar A., Ambike A.A., Jadhav B.K., Mahadik K.R. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm. 2004, 271:281-286.
32. European-Pharmacopoeia, Preparations for Inhalation Aerodynamic Assessment of Fine Particles, European Pharmacopoeia 5.0, European Councils, 2003, pp. 244-253.
33. Dunbar C., Mitchell J. Analysis of cascade impactor mass distributions. J. Aerosol Med. 2005, 18:439-451.
34. Kou X., Chan L.W., Steckel H., Heng P.W. Physico-chemical aspects of lactose for inhalation. Adv. Drug Deliv. Rev. 2012, 64:220-232.
35. Sanphui P., Goud N.R., Khandavilli U.B.R., Bhanoth S., Nangia A. New polymorphs of curcumin. Chem. Commun. 2011, 47:5013-5015.
36. Mohan P.K., Sreelakshmi G., Muraleedharan C., Joseph R. Water soluble complexes of curcumin with cyclodextrins: characterization by FT-Raman spectroscopy. Vib. Spectrosc. 2012, 62:77-84.
37. Gangwar R.K., Dhumale V.A., Kumari D., Nakate U.T., Gosavi S.W., Sharma R.B., Kale S.N., Datar S. Conjugation of curcumin with PVP capped gold nanoparticles for improving bioavailability. Mater. Sci. Eng. C 2012, 32:2659-2663.
38. Yallapu M.M., Jaggi M., Chauhan S.C. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf. B 2010, 79:113-125.
39. Duong H.T.T., Hughes F., Sagnella S., Kavallaris M., Macmillan A., Whan R., Hook J., Davis T.P., Boyer C. Functionalizing biodegradable dextran scaffolds using Living Radical Polymerization: new versatile nanoparticles for the delivery of therapeutic molecules. Mol. Pharm. 2012, 9:3046-3061.
40. Jameson D.M., Gratton E., Hall R.D. The measurement and analysis of heterogeneous emissions by multifrequency phase and modulation fluorometry. Appl. Spectrosc. Rev. 1984, 20:55-106.
41. Redford G., Clegg R. Polar plot representation for frequency-domain analysis of fluorescence lifetimes. J. Fluoresc. 2005, 15:805-815.
42. Digman M.A., Caiolfa V.R., Zamai M., Gratton E. The phasor approach to fluorescence lifetime imaging analysis. Biophys. J. 2008, 94:L14-L16.